648 results on '"Pasetti, Marcela"'
Search Results
2. Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate
3. Safety and immunogenicity of a single dose of Tdap compared to Td in pregnant women in Mali and 3 its effect on infant immune responses: a single-centre, randomised, double-blind, active-controlled phase 2 study
4. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn
5. #2547 Humoral response to COVID vaccine and infection is intact during sibeprenlimab treatment of IgAN: data from the ENVISION trial
6. Quantitative analysis of pertussis, tetanus, and diphtheria antibodies in sera and breast milk from Tdap vaccinated women using a qualified multiplex assay
7. Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond
8. mSphere of Influence: the View from the Microbiologists of the Future
9. Completion of an Experiment
10. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial
11. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers
12. Efficient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system
13. Detecting Residual Chronic Salmonella Typhi Carriers on the Road to Typhoid Elimination in Santiago, Chile, 2017–2019.
14. Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein–Based Vaccine Adjuvanted With Glucopyranosyl Lipid A–Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge
15. Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach
16. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
17. ASM Journals Eliminate Impact Factor Information from Journal Websites
18. Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies
19. Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials
20. Oral immunization with Shigella sonnei WRSs2 and WRSs3 vaccine strains elicits systemic and mucosal antibodies with functional anti-microbial activity
21. 462. Infant antibody titers at birth following maternal COVID-19 vaccination and protection against infection in the first 6 months of life
22. Evaluation of Three Candidate Live-Attenuated Salmonella enterica Serovar Typhimurium Vaccines to Prevent Non-Typhoidal Salmonella Infection in an Infant Mouse Model
23. Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection
24. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG
25. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
26. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.
27. Oral immunization with Shigella sonnei WRSs2 and WRSs3 vaccine strains elicits systemic and mucosal antibodies with functional anti-microbial activity.
28. Durable anti-Vi IgG and IgA antibody responses in 15-month-old children vaccinated with typhoid conjugate vaccine in Burkina Faso
29. Oral Shigella Vaccines
30. List of Contributors
31. Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults
32. Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward
33. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops
34. #3347 COVID VACCINE RESPONSES DURING SIBEPRENLIMAB TREATMENT OF IGA NEPHROPATHY (IGAN): AN INTERIM ANALYSIS
35. H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials
36. A Novel Shigella O-Polysaccharide–IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes
37. Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia
38. Tularemia vaccine: Safety, reactogenicity, “Take” skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain – A phase 2 randomized clinical Trial
39. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route
40. Supplementary Figure 1 from Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
41. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS‐CoV‐2
42. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial
43. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 E1 Tor
44. Dynamics of the Gut Microbiome in Shigella -Infected Children during the First Two Years of Life
45. Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study
46. Gut Immunology and Oral Vaccination
47. Mucosal immune profiles associated with diarrheal disease severity in shigella - and enteropathogenic escherichia coli-infected children enrolled in the global enteric multicenter study
48. Mucosal Immune Profiles Associated with Diarrheal Disease Severity inShigella- and Enteropathogenic Escherichia coli-Infected Children Enrolled in the Global Enteric Multicenter Study
49. Systems approach to define humoral correlates of immunity to Shigella
50. Helicobacter pylori Infection Affects Immune Responses Following Vaccination of Typhoid-Naive US Adults With Attenuated Salmonella Typhi Oral Vaccine CVD 908-htrA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.